SEC Form 4 · accession 0001648371-18-000001
Cantabio Pharmaceuticals Inc. · CTBO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gergely Toth
Officer — Chief Executive Officer · Director · 10% Owner
Period of report
Dec 17, 2015
Accepted (ET)
Oct 11, 2018 · 5:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001550518
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 17, 2015 | D | 13,500,000 | — | D | 0 | D | |
| Common StockF2 | Dec 17, 2015 | A | 10,079,147 | — | A | 10,079,147 | D | |
| Common StockF3 | Mar 27, 2018 | A | 2,400,000 | — | A | 12,479,147 | D | |
| Common StockF4 | Apr 1, 2018 | A | 3,600,000 | — | A | 16,079,147 | D | |
| Common StockF4 | Sep 12, 2018 | A | 7,352,941 | — | A | 23,432,088 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This disposition of shares returned the subject shares to the company treasury pursuant to a merger transaction.
- F2This acquisition of shares was pursuant to a merger transaction.
- F3Issued for officer and director services.
- F4Paid in lieu of cash for officer and director services.